The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Maximizing productivity of CHO cell‐based fed‐batch culture using chemically defined media conditions and typical manufacturing equipment
Abstract
A highly productive chemically defined fed‐batch process was developed to maximize titer and volumetric productivity for Chinese hamster ovary cell‐based recombinant protein manufacturing. Two cell lines producing a recombinant antibody (cell line A) and an Fc‐fusion protein (cell line B) were used for development. Both processes achieved product titers of 10 g/L on day 18 under chemically defined conditions. For cell line B, the use of plant derived hydrolysates combined with the optimized chemically defined medium increased the titer to 13 g/L. Volumetric productivities were increased from a base line of about 200 mg/L/d to about 500 mg/L/d under chemically defined conditions and as high as 700 mg/L/d with cell line B using plant derived hydrolysates. Peak cell densities reached greater than 20E6 vc/mL, and cell viabilities were maintained above 80% on day 18 without the use of antiapoptotic genes or temperature shift. A rapid compound screening method was developed to effectively test positive factors within 72 h. Peak volumetric oxygen uptake rates (OUR) more than tripled from the baseline condition. Oxygen demand continued to increase after maximum cell density was reached with a maximal OUR of 3.7 mmol/L/h. The new process format was scaled up and verified at 100 L pilot scale using reactor equipment of similar configuration as used at manufacturing scale. © 2010 American Institute of Chemical Engineers Biotechnol. Prog., 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Industrial choices for protein production by large-scale cell culture
Chu, L., & Robinson, D. K. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00197-x · Cited by 547
Cleland, J. L., Powell, M., & Shire, S. J. (1993) · PubMed · Cited by 543
Iscove, N. N., & Melchers, F. (1978) · The Journal of experimental medicine · doi:10.1084/jem.147.3.923 · Cited by 531
Birch, J. R., & Racher, A. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.006 · Cited by 471
Reactor Engineering in Large Scale Animal Cell Culture
Nienow, A. W. (2006) · Cytotechnology · doi:10.1007/s10616-006-9005-8 · Cited by 433 · cited 1×
“Typical stirred tank reactor systems used in the industry for mammalian cell culture featured mass transfer coefficients (kLa) in the order of 5–15 h 1 depending on power per volume used and the aeration strategy applied.(48) When a culture is maintained at 30% air saturation with the use of pure oxygen, the OTR achie…”
MethodProcess economics of industrial monoclonal antibody manufacture
Farid, S. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.07.037 · Cited by 389
[5] Media and growth requirements
Ham, R. G., & McKeehan, W. L. (1979) · Methods in Enzymology · doi:10.1016/s0076-6879(79)58126-9 · Cited by 333
Robinson, N. E., & Robinson, A. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221463198 · Cited by 287
Influence of low temperature on productivity, proteome and protein phosphorylation of CHO cells
Kaufmann, H., Mazur, X., Fussenegger, M., & Bailey, J. E. (1999) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19990605)63:5<573::aid-bit7>3.0.co;2-y · Cited by 278
Cited by
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Advances in recombinant antibody manufacturing
Kunert, R., & Reinhart, D. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7388-9 · Cited by 417
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Ritacco, F. V., Wu, Y., & Khetan, A. (2018) · Biotechnology Progress · doi:10.1002/btpr.2706 · Cited by 273
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176
Daramola, O., Stevenson, J., Dean, G., Hatton, D., Pettman, G., Holmes, W., & Field, R. (2014) · Biotechnology Progress · doi:10.1002/btpr.1809 · Cited by 134
CRISPR/Cas9-mediated genome engineering of CHO cell factories: application and perspectives
Lee, J. S., Grav, L. M., Lewis, N. E., & Faustrup Kildegaard, H. (2015) · Biotechnology Journal · doi:10.1002/biot.201500082 · Cited by 117
Animal-derived products in science and current alternatives
Duarte, A. C., Costa, E. C., Filipe, H. A. L., Saraiva, S. M., Jacinto, T., Miguel, S. P., Ribeiro, M. P., & Coutinho, P. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213428 · Cited by 117
Addition of Valproic Acid to CHO Cell Fed-Batch Cultures Improves Monoclonal Antibody Titers
Yang, W. C., Lu, J., Nguyen, N. B., Zhang, A., Healy, N. V., Kshirsagar, R., Ryll, T., & Huang, Y.-M. (2014) · Molecular Biotechnology · doi:10.1007/s12033-013-9725-x · Cited by 89
Self-citationHa, T. K., Kim, D., Kim, C. L., Grav, L. M., & Lee, G. M. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107831 · Cited by 74
Pasitka, L., Wissotsky, G., Ayyash, M., Yarza, N., Rosoff, G., Kaminker, R., & Nahmias, Y. (2024) · Nature Food · doi:10.1038/s43016-024-01022-w · Cited by 58
Graham, R. J., Bhatia, H., & Yoon, S. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27140 · Cited by 52
Tescione, L., Lambropoulos, J., Paranandi, M. R., Makagiansar, H., & Ryll, T. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25330 · Cited by 46
Self-citationKozma, B., Hirsch, E., Gergely, S., Párta, L., Pataki, H., & Salgó, A. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.06.070 · Cited by 41
Rajendra, Y., Peery, R. B., & Barnard, G. C. (2016) · Biotechnology Progress · doi:10.1002/btpr.2307 · Cited by 41
Carlage, T., Kshirsagar, R., Zang, L., Janakiraman, V., Hincapie, M., Lyubarskaya, Y., Weiskopf, A., & Hancock, W. S. (2012) · Biotechnology Progress · doi:10.1002/btpr.1534 · Cited by 38
Fan, L., Frye, C. C., & Racher, A. J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.56 · Cited by 35
Matthews, T. E., Smelko, J. P., Berry, B., Romero‐Torres, S., Hill, D., Kshirsagar, R., & Wiltberger, K. (2018) · Biotechnology Progress · doi:10.1002/btpr.2711 · Cited by 34
Real‐Time Nanoplasmonic Sensor for IgG Monitoring in Bioproduction
Tran, T., Eskilson, O., Mayer, F., Gustavsson, R., Selegård, R., Lundström, I., Mandenius, C.-F., Martinsson, E., & Aili, D. (2020) · Processes · doi:10.3390/pr8101302 · Cited by 24
Effects of pyruvate on primary metabolism and product quality for a high‐density perfusion process
Caso, S., Aeby, M., Jordan, M., Guillot, R., & Bielser, J. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28033 · Cited by 9
Bandyopadhyay, A., Kosanam, H., Yang, R.-S., Gupta, B., Naralakattu, N., Pakhale, S., Kress, J., Richardson, D., & Ly, J. (2022) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2022.04.008 · Cited by 7
Metadata
- Authors
- Huang, Y., Hu, W., Rustandi, E., Chang, K., Yusuf‐Makagiansar, H., & Ryll, T.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2010-04-22
- Volume
- 26
- Issue
- 5
- Pages
- 1400-1410
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2029878671
- Cited by
- 350
- References
- 47
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.